CLINICALLY PROVEN RESULTS
The main evidence for the galactagogue qualities of silymarin in expectant mothers comes from a Peruvian clinical study, which is used to support the contents of Boost. In this blinded, placebo-controlled, prospective study, 50 participants were split into two groups and given a placebo or 420 mg of micronized Silymarin daily.
Over the course of the 63-day research, there was a considerable increase in milk 3 production in the control group at 30 and 60 days. According to the researchers, "it is interesting to consider not only the quantity of produced milk in terms of absolute value but also in percentage the increase for each mother compared to day 0, which was 64.43% in the treated group and 22.51% in the placebo group." Milk production increased by 86% throughout the course of the trial, from 700.56 grams on day 0 to 1119.24 grams on day 63.
HOW DOES IT WORK?
Silymarin, an active extract from Silybum marianum (milk thistle) seeds, is present in Boost. Sixty to eighty percent silymarin flavonolignans and twenty to thirty percent chemically undefined fraction, primarily polymeric and oxidized polyphenolic chemicals, are present in a standardized extract of the seed. Rather than the seeds, silymarin is derived from the fruits of Silybum marianum (Woo et al, 2007). The range of silymarin absorption rate values is 20–50%.
According to Usman et al. (2009), there are a few possible reasons for this low bioavailability, including poor water solubility, poor enteral absorption, and breakdown by stomach fluid. In any case, silymarin's effectiveness as a new medical use is noteworthy (Gazak, 2007). At therapeutic dosages, silymarin exhibits a very high level of safety both when used alone and in conjunction with conventional therapy. (Saller R et al, 2008).
0 Comments